OSA patients with dyslipidaemia also showed higher plasma Smad4 levels than OSA patients with a normal lipid profile (634.5 ± 226.7 vs. 398.1 ± 238.7 pg/mL, p = 0.002) (Figure 6), identifying that each increase of 50 pg/mL in plasma levels of Smad4 raises the probability of concurrent dyslipidaemia, both in the crude analysis (OR 1.244, 95% CI 1.061 to 1.459, p = 0.007) and adjusted for age, sex and BMI (adjusted OR 1.318, 95% CI 1.047 to 1.659, p = 0.019). This evidence concerns the gene SMAD4 and inherited lipid metabolism disorder.